Sagar Lonial, MD, FACP, provides a look at an upcoming Virtual Tumor Board program on BCMA-directed therapies in relapsed/refractory multiple myeloma treatment.
The Role of BCMA-Directed Therapy in Relapsed/Refractory Multiple Myeloma
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
